Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to estimate the effect of a strong inhibitor of CYP3A4 (itraconazole) on the pharmacokinetics (PK) of GST-HG171/ritonavir in healthy participants.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06087055
Study type Interventional
Source Fujian Akeylink Biotechnology Co., Ltd.
Contact
Status Completed
Phase Phase 1
Start date May 12, 2023
Completion date August 7, 2023

See also
  Status Clinical Trial Phase
Completed NCT05311865 - Transmission of Covid-19 During Clubbing Events in Closed Places N/A
Recruiting NCT05520216 - Effect of Rib Cage and Spine Mobility on Maximum Breath-Hold Time
Active, not recruiting NCT04807465 - Different Modes of Universal Adhesive in Smokers and Non-Smokers N/A
Completed NCT04962022 - Drug-Drug Interaction Study Assessing Effect of Itraconazole on PF-07321332/Ritonavir in Healthy Participants Phase 1
Completed NCT04962230 - Drug-Drug Interaction Study Assessing Effect of Carbamazepine on PF-07321332 Boosted With Ritonavir Phase 1
Completed NCT05450549 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL919 in Healthy Participants Phase 1
Active, not recruiting NCT04814836 - Laser Etching Effect on Application Mode of Universal Adhesive N/A